Milestone Pharmaceuticals
MIST
44 hedge funds and large institutions have $56.4M invested in Milestone Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 7 closing their positions.
83% more capital invested
Capital invested by funds: $30.9M → $56.4M (+$25.5M)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
10% more funds holding
Funds holding: 40 → 44 (+4)
3.75% more ownership
Funds ownership: 55.24% → 58.99% (+3.7%)
86% less call options, than puts
Call options by funds: $6K | Put options by funds: $42K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.31M |
| 2 |
O
OrbiMed
New York
|
+$3.25M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.84M |
| 4 |
BlackRock
New York
|
+$2.76M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.37M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
-$1.54M |
| 2 |
Morgan Stanley
New York
|
-$908K |
| 3 |
Barclays
London,
United Kingdom
|
-$414K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$55.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$33.7K |
MIST Hedge Fund Activity: Q1 2024 in Review
44 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2024, worth a combined $56.4M — up 83% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MIST positions and 7 closed out — a net gain of 5 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.31M. The largest seller was VR Adviser, exiting entirely with an estimated $1.54M sold.
- 44 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2024, up from 40 in Q4 2023.
- Funds reported $56.4M of Milestone Pharmaceuticals stock for Q1 2024, up 83% quarter-over-quarter.
- 12 funds opened new Milestone Pharmaceuticals positions in Q1 2024 and 7 closed out, a net change of +5 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $3.31M added.
- The largest Milestone Pharmaceuticals seller in Q1 2024 was VR Adviser, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2024.